Establishing alternative methods
every new toxicological test method must pass through a defined procedure of validation and regulatory acceptance. This worldwide agreed procedure is modular, which allows a flexible application of only those modules that are necessary for a final implementation of a certain new method. As noted in Table 1 , a formal validation process aims predominantly at defining the relevance and reliability of a new testing method. This process is usually completed by a scientific review and a statement of the ECVAM Scientific Advisory Committee (ESAC). Without a positive eSAC statement, no test may be designated as "validated". However, a test method labelled as validated is not automatically applicable for regulatory purposes. Acceptance for regulatory use can be achieved only by standardisation and implementation into a test guideline, e.g. at the OECD level. Although the process of development, validation and implementation of alternative methods is extremely time consuming, the work of several institutions worldwide has been very successful, and the German ZeBet has played an important role in this process over the last 20 years. A list of alternatives to the use of animals in safety testing, which covers the requirements of the 7 th amendment of the EU Cosmetics Directive, which entered into force on March 11, 2009, is presented. 
2).
Such an Annex would keep the producers of cosmetic ingredients informed on the current status of alternative methods, especially which already meet the requirements of the Directive and which do not. Consequently, short term activities of institutions like ZeBet should focus on the following endpoints: 1. Without prejudice to the general obligations deriving from Article 2, Member States shall prohibit: (a) the marketing of cosmetic products where the final formulation, in order to meet the requirements of this Directive, has been the subject of animal testing using a method other than an alternative method after such alternative method has been validated and adopted at Community level with due regard to the development of validation within the OECD; (b) the marketing of cosmetic products containing ingredients or combinations of ingredients which, in order to meet the requirements of this Directive, have been the subject of animal testing using a method other than an alternative method after such alternative method has been validated and adopted at Community level with due regard to the development of validation within the OECD; (c) the performance on their territory of animal testing of finished cosmetic products in order to meet the requirements of this Directive; (d) the performance on their territory of animal testing of ingredients or combinations of ingredients in order to meet the requirements of this Directive, no later than the date on which such tests are required to be replaced by one or more validat-A derogation shall only be granted if: (a) the ingredient is in wide use and cannot be replaced by another ingredient able to perform a similar function; (b) the specific human health problem is substantiated and the need to conduct animal tests is justified and is supported by a detailed research Protocol proposed as the basis for the evaluation.
the decision on the authorisation, the conditions associated with it and the final result achieved shall be part of the annual report to be presented by the Commission in accordance with Article 9.
Article 9
every year the Commission shall present a report to the european Parliament and the Council on: (a) progress made in the development, validation and legal acceptance of alternative methods. The report shall contain precise data on the number and type of experiments relating to cosmetic products carried out on animals. The Member States shall be obliged to collect that information in addition to collecting statistics as laid down by Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. The Commission shall in particular ensure the development, validation and legal acceptance of alternative test methods which do not use live animals; (b) progress made by the Commission in its efforts to obtain acceptance by the OECD of alternative methods validated at Community level and recognition by non-member countries of the results of the safety tests carried out in the Community using alternative methods, in particular within the framework of cooperation agreements between the Community and these countries; (c) the manner in which the specific needs of small and mediumsized enterprises have been taken into account. and toxicokinetics, for which there are no alternatives yet under consideration. Information about the provisional and final results of these studies should form part of the yearly reports presented pursuant to Article 9.
On the basis of these annual reports, the timetables established in accordance with paragraph 2 may be adapted within a maximum time limit of six years as referred to in paragraph 2 or 10 years as referred to in paragraph 2.1 and after consultation of the entities referred to in paragraph 2.
2.3. The Commission shall study progress and compliance with the deadlines as well as possible technical difficulties in complying with the ban. Information about the provisional and final results of the Commission studies should form part of the yearly reports presented pursuant to Article 9. If these studies conclude, at the latest two years prior to the end of the maximum period referred to in paragraph 2.1, that for technical reasons one or more tests referred to in paragraph 2.1 will not be developed and validated before the expiry of the period referred to in paragraph 2.1 it shall inform the European Parliament and the Council and shall put forward a legislative proposal in accordance with Article 251 of the Treaty.
2.4. In exceptional circumstances where serious concerns arise as regards the safety of an existing cosmetic ingredient a Member Statemay request the Commission to grant a derogation from paragraph 1. The request shall contain an evaluation of the situation and indicate the measures necessary. On this basis, the Commission may, after consultation of the SCCNFP and by means of a reasoned decision, authorise the derogation in accordance with the procedure referred to in Article 10(2). This authorisation shall lay down the conditions associated with this derogation in terms of specific objectives, duration and reporting of the results.
ANNEX IX List of validated alternative methods to animal testing
this Annex lists the alternative methods validated by the european Centre on Validation of Alternative Methods (eCVAM) of the Joint Research Centre available to meet the requirements of this Directive and which are not listed in Annex V to Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. As animal testing may not be replaced completely by an alternative method, it should be mentioned in Annex Ix whether the alternative method fully or partially replaces animal testing.
